Since the mutation of TP53 was not common (approximately 2.6%) in ccRCC cases from the TCGA dataset 2 and the mutation rate of MDM2 itself was also low (Fig. 4), it was understandable that it did not show prognostic value for either OS or DFS. Here, TP53 is linked to nonpapillary renal cell carcinoma.